Immunotherapy Approved for Severe Birch Pollen Allergy in England
Here’s a breakdown of the details provided in the HTML snippet:
1. Source Attribution:
Provided by: The Conversation
Link to The Conversation: https://medicalxpress.com/partners/the-conversation/ and https://theconversation.com
The snippet indicates this article is from the Conversation, and Medical Xpress has a partnership with them.
2. Republishing Information:
Republished from: The Conversation
License: Creative Commons
Original article Link: https://theconversation.com/hay-fever-new-immunotherapy-approved-in-england-for-people-with-severe-birch-pollen-allergies-263286
Tracking Pixel: A 1×1 pixel image (https://counter.theconversation.com/content/263286/count.gif?distributor=republish-lightbox-advanced) is included to track views of the republished article.
3. Citation Information (Print Onyl):
Title: Hay fever: New immunotherapy approved in England for people with severe birch pollen allergies
* Date: August 23, 2025 (Note: This is a future date)
In essence, this snippet is a standard attribution block for a republished article, clearly stating its origin, licensing, and providing a link to the original source. It also includes a citation for print purposes.